Dear Readers, Understanding the pathological mechanisms involved in human diseases and their possible treatment has been historically based on comparative analysis of diverse animal species that share a similar genetic, physiological and behavioural composition. The ancient Greeks were the first to use animals as models for anatomy and physiology, and this was consequently adopted by other cultures and led to important discoveries. In recent years, there have been many efforts to understand and fight cancer through new revolutionary personalized treatments and wider screenings that help diagnose and treat cancer. A fundamental part of this effort is to develop suitable cancer animal models that simulate the different disease variants and their progression. Ranging from tumor-derived xenografts to genetically engineered models, a wide variety of systems are applied for this purpose, and many technological breakthroughs are changing the way cancer is studied and analyzed. In this Special Issue, we collected a set of research articles and reviews that focus on the generation of cancer animal models that are used for understanding the disease and contribute to designing and testing new drugs for cancer prevention or treatment. Vladimir Korinek Collection Editor.

Biomaterials for 3D Tumor Modeling reviews the fundamentals and most relevant areas of the latest advances of research of 3D cancer models, focusing on biomaterials science, tissue engineering, drug delivery and screening aspects. The book reviews advanced fundamental topics, including the causes of cancer, existing cancer models, angiogenesis and inflammation during cancer progression, and metastasis in 3D biomaterials. Then, the most relevant biomaterials are reviewed, including methods for engineering and fabrication of biomaterials. 3D models for key biological systems and types of cancer are also discussed, including lung, liver, oral, prostate, pancreatic, ovarian, bone and pediatric cancer. This book is suitable for those working in the disciplines of materials science, biochemistry, genetics, molecular biology, drug delivery and regenerative medicine. - Reviews key biomaterials topics, including synthetic biomaterials, hydrogels, e-spun materials and nanoparticles - Provides a comprehensive overview of 3D cancer models for key biological systems and cancer types - Includes an overview of advanced fundamental concepts for an interdisciplinary audience in materials science, biochemistry, regenerative medicine and drug delivery

This collection of 25 research papers comprised of 22 original articles and 3 reviews is brought together from international leaders in bioinformatics and biostatistics. The collection highlights recent computational advances that improve the ability to analyze highly complex data sets to identify factors critical to cancer biology. Novel deep learning algorithms represent an emerging and highly valuable approach for collecting, characterizing and predicting clinical outcomes data. The collection highlights several of these approaches that are likely to become the foundation of research and clinical practice in the future. In fact, many of these technologies reveal new insights about basic cancer mechanisms by integrating data sets and structures that were previously immiscible. Accordingly, the series presented here bring forward a wide range of artificial intelligence approaches and statistical methods that can be applied to imaging and genomics data sets to identify previously unrecognized features that are critical for cancer. Our hope is that these articles will serve as a foundation for future research as the field of cancer biology transitions to integrating electronic health record, imaging, genomics and other complex datasets in order to develop new strategies that improve the overall health of individual patients.

The meeting on experimental hepatocarcinogenesis which took place in Spa, Belgium at the end of May 1987 was the Second European Meeting. About 100 scientists, mostly from Europe but also from the United States, met there for three days in a very friendly atmosphere to exchange knowledge and ideas on experimental and human liver carcinogenesis. The main topics discussed during the meeting included general reviews on hepatocarcinogenesis, experimental models of hepa tocarcinogenesis, biology of hepatocarcinogenesis, and in vitro studies in hepatocarcinogenesis. They are all covered by the various chapters of this proceedings volume, which reflects the present state of knowledge in this important field of cancer research. The final aim of that research is to understand the basic mechanisms of carcinogenesis. The liver offers a parti cularly interesting tool to reach such a goal. Indeed, its biochemistry, its morphology, and its physiology are very diverse, but relatively well known. Various protocols have been developed to produce hepatocellular carcinomas or other malignant tumors. Their appearance is most often preceded by phenotypically altered foci and nodules which have been isolated and characterized. The major cell populations of normal, neoplastic, and malignant livers have been cultivated.

The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.

This book explores in depth the relation between physical activity and cancer control, including primary prevention, coping with treatments, recovery after treatments, long-term survivorship, secondary prevention, and survival. The first part of the book presents the most recent research on the impact of physical activity in preventing a range of cancers. In the second part, the association between physical activity and cancer survivorship is addressed. The effects of physical activity on supportive care endpoints (e.g., quality of life, fatigue, physical functioning) and disease endpoints (e.g., biomarkers, recurrence, survival) are carefully analyzed. In addition, the determinants of physical activity in cancer survivors are discussed, and behavior change strategies for increasing physical activity in cancer survivors are appraised. The final part of the book is devoted to special topics, including the relation of physical activity to pediatric cancer survivorship and to palliative cancer care.

The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.